Ameriprise
SLRN

Ameriprise’s ACELYRIN SLRN Stock Holding History

Ameriprise’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-228,098
Closed -$716K – 4135
2024
Q4 		$716K Sell
228,098
-8,564
-4% -$41.5K ﹤0.01% 3388
2024
Q3 		$1.17M Sell
236,662
-21,133
-8% -$109K ﹤0.01% 3155
2024
Q2 		$1.14M Buy
257,795
+67,092
+35% +$314K ﹤0.01% 3111
2024
Q1 		$1.29M Buy
190,703
+94,012
+97% +$714K ﹤0.01% 3068
2023
Q4 		$721K Buy
96,691
+28,618
+42% +$244K ﹤0.01% 3316
2023
Q3 		$692K Sell
68,073
-336,750
-83% -$7.15M ﹤0.01% 3290
2023
Q2 		$8.46M Buy
+404,823
New +$8.28M ﹤0.01% 1916

Other funds holding SLRN

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Ameriprise's SLRN Position: Q1 2025 in Review

Ameriprise sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 228,098 shares — an estimated $716K sold.

Ameriprise first reported a position in SLRN in Q2 2023 and held it in 7 quarters. The position peaked at $8.46M in Q2 2023. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • Ameriprise reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • Ameriprise sold 228,098 ACELYRIN shares in Q1 2025, an estimated $716K.
  • Ameriprise first reported a position in ACELYRIN in Q2 2023 and held it in 7 quarters.
  • Ameriprise's ACELYRIN position peaked at $8.46M in Q2 2023.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on Ameriprise's 13F filing for Q1 2025, filed 14 May 2025.